[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: early post-esophagectomy (18 days), tracheobronchial-gastric conduit fistula, sepsis, CT/bronchoscopy confirmation. These indicate an acute, infected, life-threatening anastomotic complication requiring urgent surgical intervention. The keyed answer (emergency thoracotomy with repair using muscle flap, conduit resection, and cervical esophagostomy) aligns with standard surgical principles for managing early postoperative conduit-airway fistulas: control sepsis, resect ischemic conduit, repair with vascularized tissue, and plan delayed reconstruction. Alternatives are inferior: endoscopic stenting (A) has high failure in early postoperative setting; conservative NPO/antibiotics (C) ignores need for source control; fibrin glue (D) is inadequate for large fistula; conduit abandonment without repair (E) leaves ongoing contamination. No contradictions or underspecification; unique best answer is defensible. Medical accuracy is consistent with thoracic surgery guidelines. Minimal fix: none needed for validity; could add 'despite broad-spectrum antibiotics' to emphasize failure of medical management alone.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: early post-esophagectomy (18 days), tracheobronchial-gastric conduit fistula, sepsis, CT/bronchoscopy confirmation. These indicate an acute, infected, life-threatening anastomotic complication requiring urgent surgical intervention. The keyed answer (emergency thoracotomy with repair using muscle flap, conduit resection, and cervical esophagostomy) aligns with standard surgical principles for managing early postoperative conduit-airway fistulas: control sepsis, resect ischemic conduit, repair with vascularized tissue, and plan delayed reconstruction. Alternatives are inferior: endoscopic stenting (A) has high failure in early postoperative setting; conservative NPO/antibiotics (C) ignores need for source control; fibrin glue (D) is inadequate for large fistula; conduit abandonment without repair (E) leaves ongoing contamination. No contradictions or underspecification; unique best answer is defensible. Medical accuracy is consistent with thoracic surgery guidelines. Minimal fix: none needed for validity; could add 'despite broad-spectrum antibiotics' to emphasize failure of medical management alone.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: acute mesenteric venous thrombosis (MVT) with viable bowel in a patient with antiphospholipid syndrome. The standard of care for acute MVT with signs of ischemia but viable bowel is immediate systemic anticoagulation (e.g., heparin) to prevent thrombus progression, not catheter-directed thrombolysis (CDT) as the first-line 'most appropriate next step.' CDT is a potential rescue therapy for select cases but is not the initial, definitive management. The keyed answer (C) is not the single best answer. The most appropriate next step is immediate systemic anticoagulation, best represented by option B (heparin infusion). Main logical issue: a unique best answer exists (B), but the provided key (C) is incorrect. Main medical accuracy issue: overstates the role of CDT as first-line therapy. Minimal fix: Change the key to B and adjust the rationale to reflect that systemic anticoagulation is the immediate, cornerstone therapy for acute MVT.\",\n  \"medical_accuracy_score\":  \"3\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: acute mesenteric venous thrombosis (MVT) with viable bowel in a patient with antiphospholipid syndrome. The standard of care for acute MVT with signs of ischemia but viable bowel is immediate systemic anticoagulation (e.g., heparin) to prevent thrombus progression, not catheter-directed thrombolysis (CDT) as the first-line 'most appropriate next step.' CDT is a potential rescue therapy for select cases but is not the initial, definitive management. The keyed answer (C) is not the single best answer. The most appropriate next step is immediate systemic anticoagulation, best represented by option B (heparin infusion). Main logical issue: a unique best answer exists (B), but the provided key (C) is incorrect. Main medical accuracy issue: overstates the role of CDT as first-line therapy. Minimal fix: Change the key to B and adjust the rationale to reflect that systemic anticoagulation is the immediate, cornerstone therapy for acute MVT.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: MEN1 syndrome, 2.8 cm duodenal gastrinoma with regional lymph node metastases, no pancreatic lesions. The findings indicate a localized but metastatic duodenal primary requiring curative-intent resection with lymphadenectomy. The keyed answer (B) is the standard oncologic surgery for this scenario, aiming for complete tumor and nodal clearance while preserving the pancreas for future potential surgery. Alternatives are inferior: Whipple (A) is overly morbid for duodenal-only disease; endoscopic resection (C) is inadequate for nodal metastases; octreotide (D) is not curative for resectable disease; and enucleation only (E) fails to address nodal disease. No internal contradictions or missing critical details exist. The item is medically accurate and logically valid. A minimal fix is not required.\",\n    \"medical_accuracy_score\":  \"5\",\n    \"logical_validity\": true,\n    \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: MEN1 syndrome, 2.8 cm duodenal gastrinoma with regional lymph node metastases, no pancreatic lesions. The findings indicate a localized but metastatic duodenal primary requiring curative-intent resection with lymphadenectomy. The keyed answer (B) is the standard oncologic surgery for this scenario, aiming for complete tumor and nodal clearance while preserving the pancreas for future potential surgery. Alternatives are inferior: Whipple (A) is overly morbid for duodenal-only disease; endoscopic resection (C) is inadequate for nodal metastases; octreotide (D) is not curative for resectable disease; and enucleation only (E) fails to address nodal disease. No internal contradictions or missing critical details exist. The item is medically accurate and logically valid. A minimal fix is not required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: painful hepatomegaly, ascites, jaundice, and elevated bilirubin/ALT/INR occurring 3 weeks post-oxaliplatin-based chemotherapy (FOLFOX), with biopsy showing sinusoidal congestion and zone 3 necrosis without portal inflammation. This pattern is classic for severe sinusoidal obstruction syndrome (SOS, formerly VOD). The definitive therapy for severe SOS is defibrotide. The keyed answer (B) aligns with this. Alternatives are incorrect: steroids are not effective for SOS; TIPS is contraindicated due to diffuse sinusoidal injury; N-acetylcysteine is for acetaminophen toxicity; urgent transplant is not indicated without fulminant hepatic failure/encephalopathy. The item is logically valid, medically accurate, and supports a single best answer. Minimal fix: None required; item is sound.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: painful hepatomegaly, ascites, jaundice, and elevated bilirubin/ALT/INR occurring 3 weeks post-oxaliplatin-based chemotherapy (FOLFOX), with biopsy showing sinusoidal congestion and zone 3 necrosis without portal inflammation. This pattern is classic for severe sinusoidal obstruction syndrome (SOS, formerly VOD). The definitive therapy for severe SOS is defibrotide. The keyed answer (B) aligns with this. Alternatives are incorrect: steroids are not effective for SOS; TIPS is contraindicated due to diffuse sinusoidal injury; N-acetylcysteine is for acetaminophen toxicity; urgent transplant is not indicated without fulminant hepatic failure/encephalopathy. The item is logically valid, medically accurate, and supports a single best answer. Minimal fix: None required; item is sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CFH p.Arg1215Gln mutation (atypical HUS risk), deceased donor kidney transplant, post-op day 7 features of thrombotic microangiopathy (rising creatinine, thrombocytopenia, schistocytes, hemolysis) despite preemptive eculizumab started day 0. Platelets normalized by day 10 but creatinine continued to rise, indicating possible breakthrough HUS. The question asks for the next step in management. The keyed answer D (measure eculizumab trough level and CH50 activity) is the standard approach to assess for subtherapeutic drug levels or complement breakthrough before escalating therapy. Alternatives: A (increase dose) is premature without monitoring; B (plasma exchange) is ineffective in eculizumab-treated atypical HUS; C (switch to ravulizumab) is not indicated without assessing eculizumab levels; E (nephrectomy) is extreme. The item is logically valid: a unique best answer exists and matches the key. Medical accuracy is consistent with current guidelines for managing breakthrough HUS on eculizumab. Minimal fix: None needed; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CFH p.Arg1215Gln mutation (atypical HUS risk), deceased donor kidney transplant, post-op day 7 features of thrombotic microangiopathy (rising creatinine, thrombocytopenia, schistocytes, hemolysis) despite preemptive eculizumab started day 0. Platelets normalized by day 10 but creatinine continued to rise, indicating possible breakthrough HUS. The question asks for the next step in management. The keyed answer D (measure eculizumab trough level and CH50 activity) is the standard approach to assess for subtherapeutic drug levels or complement breakthrough before escalating therapy. Alternatives: A (increase dose) is premature without monitoring; B (plasma exchange) is ineffective in eculizumab-treated atypical HUS; C (switch to ravulizumab) is not indicated without assessing eculizumab levels; E (nephrectomy) is extreme. The item is logically valid: a unique best answer exists and matches the key. Medical accuracy is consistent with current guidelines for managing breakthrough HUS on eculizumab. Minimal fix: None needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: Day +45 post-allo-SCT, hypertension, proteinuria, hemolysis, thrombocytopenia, rising LDH, ADAMTS13 activity 45% (not severely deficient), tacrolimus stopped 14 days prior. The presentation is highly suggestive of transplant-associated thrombotic microangiopathy (TA-TMA). The keyed answer (A, eculizumab) is a plausible and guideline-supported therapy for high-risk TA-TMA. However, the stem lacks critical details to uniquely select eculizumab over high-dose steroids plus plasma exchange (option B), which is also a first-line intervention for TA-TMA in many centers, especially if there is concern for concurrent acute GVHD or if complement blockade is not immediately available. The item is underspecified regarding the presence of active GVHD, organ dysfunction severity, and institutional protocols, making both A and B defensible. The logical failure is primarily miskeying because a unique best answer is not established, but the deeper issue is underspecification (U) leading to multiple defensible answers (M). Main medical accuracy issue: The rationale incorrectly states plasma exchange is 'ineffective'; it is often used initially while arranging eculizumab. Minimal fix: Specify 'no improvement after 3 days of high-dose methylprednisolone and plasma exchange' to make eculizumab the clear next step.\", \"logical_false_reason\": \"K\", \"logical_validity\": false, \"medical_accuracy_score\": \t\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: Day +45 post-allo-SCT, hypertension, proteinuria, hemolysis, thrombocytopenia, rising LDH, ADAMTS13 activity 45% (not severely deficient), tacrolimus stopped 14 days prior. The presentation is highly suggestive of transplant-associated thrombotic microangiopathy (TA-TMA). The keyed answer (A, eculizumab) is a plausible and guideline-supported therapy for high-risk TA-TMA. However, the stem lacks critical details to uniquely select eculizumab over high-dose steroids plus plasma exchange (option B), which is also a first-line intervention for TA-TMA in many centers, especially if there is concern for concurrent acute GVHD or if complement blockade is not immediately available. The item is underspecified regarding the presence of active GVHD, organ dysfunction severity, and institutional protocols, making both A and B defensible. The logical failure is primarily miskeying because a unique best answer is not established, but the deeper issue is underspecification (U) leading to multiple defensible answers (M). Main medical accuracy issue: The rationale incorrectly states plasma exchange is 'ineffective'; it is often used initially while arranging eculizumab. Minimal fix: Specify 'no improvement after 3 days of high-dose methylprednisolone and plasma exchange' to make eculizumab the clear next step.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CANDLE syndrome (PSMB8 mutation), failure of IL-1 blockade (anakinra and canakinumab). The vignette specifies a type I interferonopathy refractory to IL-1 inhibition, making JAK inhibition the next logical targeted therapy. Main logical issue: None; the item is well-specified. Main medical accuracy issue: None; the rationale aligns with current literature on JAK inhibitors for refractory CANDLE syndrome. Minimal fix: None required; the item is clear and accurate.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CANDLE syndrome (PSMB8 mutation), failure of IL-1 blockade (anakinra and canakinumab). The vignette specifies a type I interferonopathy refractory to IL-1 inhibition, making JAK inhibition the next logical targeted therapy. Main logical issue: None; the item is well-specified. Main medical accuracy issue: None; the rationale aligns with current literature on JAK inhibitors for refractory CANDLE syndrome. Minimal fix: None required; the item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Patient from Vietnam (endemic region) with chronic mucocutaneous candidiasis and STAT1 GOF mutation presents with disseminated umbilicated papules, hepatosplenomegaly, fever, and biopsy showing intracellular yeast with central septation—classic for Talaromyces marneffei. The optimal therapy for disseminated T. marneffei in an immunodeficient host (STAT1 GOF) is induction with amphotericin B followed by itraconazole maintenance, plus JAK inhibition (e.g., ruxolitinib) to address the underlying immune defect, making option C uniquely correct. No logical issues; the vignette provides sufficient detail for a single best answer. Medical accuracy is sound, reflecting current understanding of managing T. marneffei in STAT1 GOF. Minimal fix: None required; the item is clear and accurate.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Patient from Vietnam (endemic region) with chronic mucocutaneous candidiasis and STAT1 GOF mutation presents with disseminated umbilicated papules, hepatosplenomegaly, fever, and biopsy showing intracellular yeast with central septation—classic for Talaromyces marneffei. The optimal therapy for disseminated T. marneffei in an immunodeficient host (STAT1 GOF) is induction with amphotericin B followed by itraconazole maintenance, plus JAK inhibition (e.g., ruxolitinib) to address the underlying immune defect, making option C uniquely correct. No logical issues; the vignette provides sufficient detail for a single best answer. Medical accuracy is sound, reflecting current understanding of managing T. marneffei in STAT1 GOF. Minimal fix: None required; the item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: severe fatigue, hypotension, hyponatremia, headache, and pituitary enlargement point to hypophysitis (likely adrenal insufficiency). Elevated troponin with normal EF suggests myocarditis. Both are immune-related adverse events (irAEs) from ipilimumab/nivolumab. Immediate management for severe, life-threatening dual irAEs (adrenal crisis + myocarditis) is high-dose corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day) and hormone replacement (e.g., stress-dose hydrocortisone). The keyed answer (C) adds mycophenolate mofetil, which is a steroid-sparing agent for refractory cases, not immediate first-line. Option A (methylprednisolone alone) is the standard initial therapy; adding a second agent immediately is not typical. The stem lacks details indicating steroid-refractory disease, making A the best initial step. Main logical issue: key mismatch. Main medical accuracy issue: premature addition of mycophenolate. Minimal fix: Change key to A and adjust rationale to state high-dose steroids are first-line, with mycophenolate reserved for refractory cases.\", \"logical_false_reason\": \"K\", \"logical_validity\": false, \"medical_accuracy_score\": \t\"3\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: severe fatigue, hypotension, hyponatremia, headache, and pituitary enlargement point to hypophysitis (likely adrenal insufficiency). Elevated troponin with normal EF suggests myocarditis. Both are immune-related adverse events (irAEs) from ipilimumab/nivolumab. Immediate management for severe, life-threatening dual irAEs (adrenal crisis + myocarditis) is high-dose corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day) and hormone replacement (e.g., stress-dose hydrocortisone). The keyed answer (C) adds mycophenolate mofetil, which is a steroid-sparing agent for refractory cases, not immediate first-line. Option A (methylprednisolone alone) is the standard initial therapy; adding a second agent immediately is not typical. The stem lacks details indicating steroid-refractory disease, making A the best initial step. Main logical issue: key mismatch. Main medical accuracy issue: premature addition of mycophenolate. Minimal fix: Change key to A and adjust rationale to state high-dose steroids are first-line, with mycophenolate reserved for refractory cases.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, elevated baseline tryptase, confirmed hereditary alpha-tryptasemia (HATS), and failure of high-dose cetirizine and omalizumab. This defines a refractory mast cell activation syndrome. Main logical issue: None; the stem uniquely points to a mast cell stabilizer as the next step after antihistamine and anti-IgE failure. Main medical accuracy issue: Minor; ketotifen is a reasonable next-line mast cell stabilizer for HATS, though its use is somewhat off-label and not universally standardized, but it aligns with expert consensus for refractory symptoms. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'refractory mast cell activation symptoms' to reinforce the rationale for mast cell stabilizer over other options.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, elevated baseline tryptase, confirmed hereditary alpha-tryptasemia (HATS), and failure of high-dose cetirizine and omalizumab. This defines a refractory mast cell activation syndrome. Main logical issue: None; the stem uniquely points to a mast cell stabilizer as the next step after antihistamine and anti-IgE failure. Main medical accuracy issue: Minor; ketotifen is a reasonable next-line mast cell stabilizer for HATS, though its use is somewhat off-label and not universally standardized, but it aligns with expert consensus for refractory symptoms. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'refractory mast cell activation symptoms' to reinforce the rationale for mast cell stabilizer over other options.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: bilateral lung transplant 6 hours ago, severe hypoxemia (PaO2/FiO2 85 on 100% FiO2) despite inhaled nitric oxide and optimal ventilation, diffuse bilateral infiltrates on CXR, implying severe primary graft dysfunction (PGD) grade 3 requiring full respiratory support. The question asks for optimal mechanical support strategy. The keyed answer (E) is veno-venous ECMO via a dual-lumen cannula, which is a standard advanced support for severe PGD post-lung transplant, allowing oxygenation and potential mobilization. Alternatives are inferior: A (femoral-jugular VV-ECMO) limits mobility; B (VA-ECMO) is for cardiac failure, not indicated here; C (ECCO2R) provides inadequate oxygenation for severe hypoxemia; D (inhaled epoprostenol only) is insufficient as a rescue therapy. No contradictions or missing critical details. Medical accuracy is sound, aligning with standard management for PGD grade 3. Minimal fix: none needed for logical validity; to enhance clarity, the stem could explicitly state 'no signs of cardiac dysfunction' to preempt VA-ECMO consideration.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\": \t\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: bilateral lung transplant 6 hours ago, severe hypoxemia (PaO2/FiO2 85 on 100% FiO2) despite inhaled nitric oxide and optimal ventilation, diffuse bilateral infiltrates on CXR, implying severe primary graft dysfunction (PGD) grade 3 requiring full respiratory support. The question asks for optimal mechanical support strategy. The keyed answer (E) is veno-venous ECMO via a dual-lumen cannula, which is a standard advanced support for severe PGD post-lung transplant, allowing oxygenation and potential mobilization. Alternatives are inferior: A (femoral-jugular VV-ECMO) limits mobility; B (VA-ECMO) is for cardiac failure, not indicated here; C (ECCO2R) provides inadequate oxygenation for severe hypoxemia; D (inhaled epoprostenol only) is insufficient as a rescue therapy. No contradictions or missing critical details. Medical accuracy is sound, aligning with standard management for PGD grade 3. Minimal fix: none needed for logical validity; to enhance clarity, the stem could explicitly state 'no signs of cardiac dysfunction' to preempt VA-ECMO consideration.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: infrarenal AAA >5.5 cm (meets size threshold for repair), thick circumferential periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, elevated inflammatory markers (ESR/CRP). This combination defines inflammatory abdominal aortic aneurysm (IAAA). Main logical issue: None. Main medical accuracy issue: None; the sequence aligns with standard vascular surgery principles for IAAA: initial high-dose corticosteroids to reduce inflammation and relieve ureteral compression, followed by definitive aneurysm repair. EVAR is preferred over open repair in this inflammatory setting due to reduced morbidity. Minimal fix: None required for a valid item. The stem clearly presents the classic triad of IAAA (AAA, periaortic fibrosis, ureteral involvement) and the options logically test the management sequence.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: infrarenal AAA >5.5 cm (meets size threshold for repair), thick circumferential periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, elevated inflammatory markers (ESR/CRP). This combination defines inflammatory abdominal aortic aneurysm (IAAA). Main logical issue: None. Main medical accuracy issue: None; the sequence aligns with standard vascular surgery principles for IAAA: initial high-dose corticosteroids to reduce inflammation and relieve ureteral compression, followed by definitive aneurysm repair. EVAR is preferred over open repair in this inflammatory setting due to reduced morbidity. Minimal fix: None required for a valid item. The stem clearly presents the classic triad of IAAA (AAA, periaortic fibrosis, ureteral involvement) and the options logically test the management sequence.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: metastatic glucagonoma (diffuse hepatic metastases) with hormone-related symptoms (necrolytic migratory erythema, new-onset diabetes, high glucagon). First-line therapy for symptomatic, metastatic, well-differentiated (Ki-67 8%) pancreatic neuroendocrine tumor (glucagonoma) is a somatostatin analog (octreotide or lanreotide) for symptom control and antiproliferative effect. Both octreotide LAR and lanreotide are first-line options; guidelines consider them equivalent with similar efficacy. The stem does not provide a reason to prefer lanreotide over octreotide LAR (e.g., patient preference, dosing convenience, or specific trial data). Thus, options B and C are equally defensible as first-line, making the key arbitrary. Main logical issue: M (Multiple answers defensible) also applies because B and C are therapeutic equivalents. Main medical accuracy issue: The rationale incorrectly states lanreotide is 'preferred over octreotide LAR due to consistent dosing,' which is not a guideline-based distinction for first-line selection; both are acceptable. Minimal fix: Remove either B or C to eliminate the duplicate first-line somatostatin analog option, or specify a patient factor (e.g., 'patient prefers deep subcutaneous injections') to discriminate.\", \"logical_false_reason\": \"K\", \"logical_validity\": false, \"medical_accuracy_score\":  \"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: metastatic glucagonoma (diffuse hepatic metastases) with hormone-related symptoms (necrolytic migratory erythema, new-onset diabetes, high glucagon). First-line therapy for symptomatic, metastatic, well-differentiated (Ki-67 8%) pancreatic neuroendocrine tumor (glucagonoma) is a somatostatin analog (octreotide or lanreotide) for symptom control and antiproliferative effect. Both octreotide LAR and lanreotide are first-line options; guidelines consider them equivalent with similar efficacy. The stem does not provide a reason to prefer lanreotide over octreotide LAR (e.g., patient preference, dosing convenience, or specific trial data). Thus, options B and C are equally defensible as first-line, making the key arbitrary. Main logical issue: M (Multiple answers defensible) also applies because B and C are therapeutic equivalents. Main medical accuracy issue: The rationale incorrectly states lanreotide is 'preferred over octreotide LAR due to consistent dosing,' which is not a guideline-based distinction for first-line selection; both are acceptable. Minimal fix: Remove either B or C to eliminate the duplicate first-line somatostatin analog option, or specify a patient factor (e.g., 'patient prefers deep subcutaneous injections') to discriminate.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: chronic iron deficiency anemia requiring IV iron (suggests chronic blood loss), recurrent partial small bowel obstruction, capsule endoscopy shows 5 short ulcerated strictures in proximal jejunum, biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions (excludes Crohn's, NSAID enteropathy, lymphoma, and refractory celiac). Main logical issue: None; the findings uniquely point to CMUSE by excluding other causes. Main medical accuracy issue: None; the description and management with budesonide align with published literature on this rare entity. Minimal fix: None required; the item is clear and accurate. The explanation correctly notes the need to exclude Crohn's and NSAID use, and the risk of capsule retention.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 945)"}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: HIV-positive man on tenofovir with hypophosphatemia, phosphaturia, glucosuria, and metabolic acidosis, consistent with tenofovir-induced Fanconi syndrome. The question asks for the 'optimal electrolyte replacement regimen.' The keyed answer (D) suggests oral sodium phosphate plus sodium bicarbonate. However, the rationale states 'stopping tenofovir is necessary,' making option E ('Stop tenofovir only') a critical, missing component of optimal management. The stem does not specify if tenofovir is being discontinued, creating an unstated assumption. In standard care, the cornerstone is stopping the offending drug (tenofovir) and replacing losses; thus, a combination of stopping the drug and replacing electrolytes is optimal, but no single option reflects this. This leads to multiple defensible answers (M secondary), as both D and E have merit, but the key selects D without acknowledging the necessity of E. Main medical accuracy issue: The key omits the essential step of drug discontinuation. Minimal fix: Revise the stem to specify 'The patient's tenofovir is being discontinued. What is the optimal electrolyte replacement regimen?' or adjust options to include both cessation and replacement.\",\n  \"medical_accuracy_score\":  \"3\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: HIV-positive man on tenofovir with hypophosphatemia, phosphaturia, glucosuria, and metabolic acidosis, consistent with tenofovir-induced Fanconi syndrome. The question asks for the 'optimal electrolyte replacement regimen.' The keyed answer (D) suggests oral sodium phosphate plus sodium bicarbonate. However, the rationale states 'stopping tenofovir is necessary,' making option E ('Stop tenofovir only') a critical, missing component of optimal management. The stem does not specify if tenofovir is being discontinued, creating an unstated assumption. In standard care, the cornerstone is stopping the offending drug (tenofovir) and replacing losses; thus, a combination of stopping the drug and replacing electrolytes is optimal, but no single option reflects this. This leads to multiple defensible answers (M secondary), as both D and E have merit, but the key selects D without acknowledging the necessity of E. Main medical accuracy issue: The key omits the essential step of drug discontinuation. Minimal fix: Revise the stem to specify 'The patient's tenofovir is being discontinued. What is the optimal electrolyte replacement regimen?' or adjust options to include both cessation and replacement.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CHIP with JAK2 V617F mutation at 12% VAF, normal CBC, no splenomegaly, and no overt myeloproliferative neoplasm (MPN). These findings exclude overt MPN (e.g., polycythemia vera) where higher thrombosis risk and cytoreductive therapy apply. The item correctly isolates the CHIP-specific risk and management. Main logical issue: None; the stem provides sufficient detail to discriminate. Main medical accuracy issue: The stated 0.5% annual risk is at the lower end of the reported range (0.5–1%), but this is a minor nuance; low-dose aspirin for primary prophylaxis in JAK2-mutated CHIP is supported by observational data and guideline considerations. Minimal fix: Specify 'in the absence of overt MPN' in the stem to preempt any confusion with MPN management, though the normal CBC and lack of splenomegaly already imply this.\",\n  \"medical_accuracy_score\":  \"4\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: CHIP with JAK2 V617F mutation at 12% VAF, normal CBC, no splenomegaly, and no overt myeloproliferative neoplasm (MPN). These findings exclude overt MPN (e.g., polycythemia vera) where higher thrombosis risk and cytoreductive therapy apply. The item correctly isolates the CHIP-specific risk and management. Main logical issue: None; the stem provides sufficient detail to discriminate. Main medical accuracy issue: The stated 0.5% annual risk is at the lower end of the reported range (0.5–1%), but this is a minor nuance; low-dose aspirin for primary prophylaxis in JAK2-mutated CHIP is supported by observational data and guideline considerations. Minimal fix: Specify 'in the absence of overt MPN' in the stem to preempt any confusion with MPN management, though the normal CBC and lack of splenomegaly already imply this.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: recurrent sinopulmonary infections with S. pneumoniae, SLE-like malar rash, low C1q with normal C1r/C1s, homozygous C1QA mutation. This defines classical complement pathway deficiency (C1q deficiency), which predisposes to encapsulated bacterial infections, especially pneumococcus. Main logical issue: None; the vignette is specific and consistent. Main medical accuracy issue: None; lifelong penicillin prophylaxis is standard for complement deficiencies to prevent pneumococcal disease. Minimal fix: None needed; the item is clear and accurate. Alternative B (IVIG) is for antibody deficiencies, not isolated complement deficiency. C is incorrect due to infection risk. D is unnecessary (no fungal risk). E is insufficient alone.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: recurrent sinopulmonary infections with S. pneumoniae, SLE-like malar rash, low C1q with normal C1r/C1s, homozygous C1QA mutation. This defines classical complement pathway deficiency (C1q deficiency), which predisposes to encapsulated bacterial infections, especially pneumococcus. Main logical issue: None; the vignette is specific and consistent. Main medical accuracy issue: None; lifelong penicillin prophylaxis is standard for complement deficiencies to prevent pneumococcal disease. Minimal fix: None needed; the item is clear and accurate. Alternative B (IVIG) is for antibody deficiencies, not isolated complement deficiency. C is incorrect due to infection risk. D is unnecessary (no fungal risk). E is insufficient alone.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. The stem describes a patient on deferoxamine with a cavitary lung lesion and biopsy showing broad nonseptate hyphae with right-angle branching, classic for mucormycosis. The keyed answer (D) suggests amphotericin B plus deferasirox. While deferoxamine cessation is critical and deferasirox has shown in vitro and some clinical antifungal synergy, the current standard of care for mucormycosis is high-dose liposomal amphotericin B monotherapy as initial therapy. Combination therapy with an azole (e.g., posaconazole or isavuconazole) is considered in refractory cases or as step-down oral therapy, but the combination of amphotericin B with deferasirox is not established as the optimal initial combination. Option B (Amphotericin B plus posaconazole) is a more widely accepted and guideline-supported combination for severe or refractory mucormycosis. The stem lacks details (e.g., severity, refractoriness) to justify deferasirox combination as the singular 'optimal' choice over a standard azole combination, making D miskeyed. Main medical accuracy issue: Overstates the role of deferasirox combination as first-line optimal therapy. Minimal fix: Change key to B and adjust rationale to reflect guideline-supported combinations.\", \"logical_false_reason\": \"K\", \"logical_validity\": false, \"medical_accuracy_score\": \t\"3\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. The stem describes a patient on deferoxamine with a cavitary lung lesion and biopsy showing broad nonseptate hyphae with right-angle branching, classic for mucormycosis. The keyed answer (D) suggests amphotericin B plus deferasirox. While deferoxamine cessation is critical and deferasirox has shown in vitro and some clinical antifungal synergy, the current standard of care for mucormycosis is high-dose liposomal amphotericin B monotherapy as initial therapy. Combination therapy with an azole (e.g., posaconazole or isavuconazole) is considered in refractory cases or as step-down oral therapy, but the combination of amphotericin B with deferasirox is not established as the optimal initial combination. Option B (Amphotericin B plus posaconazole) is a more widely accepted and guideline-supported combination for severe or refractory mucormycosis. The stem lacks details (e.g., severity, refractoriness) to justify deferasirox combination as the singular 'optimal' choice over a standard azole combination, making D miskeyed. Main medical accuracy issue: Overstates the role of deferasirox combination as first-line optimal therapy. Minimal fix: Change key to B and adjust rationale to reflect guideline-supported combinations.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: subacute cerebellar ataxia, anti-Yo antibodies, lymphocytic pleocytosis in a patient with ovarian cancer. Main logical issue: The stem asks for 'immunotherapy protocol' but does not specify the clinical goal (e.g., acute stabilization, long-term maintenance, or first-line vs. refractory treatment). This missing detail makes the choice between options like cyclophosphamide (C), IVIG (B), and rituximab (D) dependent on unstated assumptions about treatment phase and institutional guidelines, as multiple immunotherapies are used in paraneoplastic syndromes. Main medical accuracy issue: While cyclophosphamide is a plausible option, the rationale overstates its superiority; rituximab and IVIG are also supported in guidelines, and cyclophosphamide's blood-brain barrier penetration is limited. Minimal fix: Specify the treatment context, e.g., 'first-line immunotherapy for acute stabilization' or 'after failure of initial steroids,' to justify a unique best answer.\",\n  \"logical_false_reason\": \"U\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: subacute cerebellar ataxia, anti-Yo antibodies, lymphocytic pleocytosis in a patient with ovarian cancer. Main logical issue: The stem asks for 'immunotherapy protocol' but does not specify the clinical goal (e.g., acute stabilization, long-term maintenance, or first-line vs. refractory treatment). This missing detail makes the choice between options like cyclophosphamide (C), IVIG (B), and rituximab (D) dependent on unstated assumptions about treatment phase and institutional guidelines, as multiple immunotherapies are used in paraneoplastic syndromes. Main medical accuracy issue: While cyclophosphamide is a plausible option, the rationale overstates its superiority; rituximab and IVIG are also supported in guidelines, and cyclophosphamide's blood-brain barrier penetration is limited. Minimal fix: Specify the treatment context, e.g., 'first-line immunotherapy for acute stabilization' or 'after failure of initial steroids,' to justify a unique best answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: DRESS syndrome (fever, facial edema, rash, eosinophilia, atypical lymphocytes, hepatitis) triggered by allopurinol at 3 weeks. Hepatitis (AST/ALT >10x ULN) indicates severe systemic involvement requiring systemic corticosteroids. The keyed answer (B) specifies IV methylprednisolone with a slow 8-12 week taper, which aligns with guideline recommendations for severe DRESS with organ involvement to prevent relapse. Option A (oral prednisone, 2-week taper) is too rapid and risks rebound. Option C (pulse only) is insufficient. Options D and E (no systemic steroids) are inadequate for severe hepatitis. No contradictions or missing critical details; a unique best answer is supported. Medical accuracy is high. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'severe DRESS syndrome with hepatitis' to reinforce the need for prolonged systemic steroids.\", \"logical_false_reason\": \"T\", \"logical_validity\": true, \"medical_accuracy_score\":  \"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: DRESS syndrome (fever, facial edema, rash, eosinophilia, atypical lymphocytes, hepatitis) triggered by allopurinol at 3 weeks. Hepatitis (AST/ALT >10x ULN) indicates severe systemic involvement requiring systemic corticosteroids. The keyed answer (B) specifies IV methylprednisolone with a slow 8-12 week taper, which aligns with guideline recommendations for severe DRESS with organ involvement to prevent relapse. Option A (oral prednisone, 2-week taper) is too rapid and risks rebound. Option C (pulse only) is insufficient. Options D and E (no systemic steroids) are inadequate for severe hepatitis. No contradictions or missing critical details; a unique best answer is supported. Medical accuracy is high. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'severe DRESS syndrome with hepatitis' to reinforce the need for prolonged systemic steroids.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]